Supernus Pharmaceuticals, Inc.(SUPN)

Description: Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.

---

Keywords: Pharmaceutical Drug Discovery Clinical Trial Clinical Research Depression Chloride Epilepsy Neurology Attention Deficit Hyperactivity Disorder Central Nervous System Disease Treatment Of Depression Clinical Trial Product Hyperactivity Disorder Treatment Of Epilepsy Investigational New Drug Topiramate Treatment Of Central Nervous System Diseases

---

Home Page: www.supernus.com

SUPN Technical Analysis

9715 Key West Avenue
Rockville, MD 20850
United States
Phone: 301 838 2500

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)